Journal
CANCER
Volume 103, Issue 12, Pages 2435-2446Publisher
WILEY
DOI: 10.1002/cncr.21123
Keywords
colorectal carcinoma; epidermal growth factor receptor; IMC-C225; cetuximab; bevacizumab; targeted chemotherapy
Categories
Ask authors/readers for more resources
Substantial effort has focused on the development of novel targeted agents for treating patients with late-stage colorectal carcinoma. These agents are designed specifically to inhibit biochemical processes associated with pathogenesis. Numerous molecules targeting the epidermal growth factor receptor have been investigated as therapeutic agents and appear to herald a shift in the treatment paradigm for colorectal carcinoma. (c) 2005 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available